



*Ifw*

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Re Application of

Group Art Unit: 1631

YOKOYA *et al.*

Examiner: WHALEY, Pablo S.

Serial No.: 10/771,337

Filed: February 5, 2004

For: **GENE PANEL PARTICIPATIVE IN HEPATIC STELLATE CELL ACTIVATION**

**TRANSMITTAL LETTER**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

Submitted herewith for filing in the U.S. Patent and Trademark Office is the following:

- 1) Transmittal Letter, one (1) page;
- 2) Information Disclosure Statement, two (2) pages;
- 3) PTO Form 1449 citing one (1) reference, one (1) page; and
- 4) One (1) reference attached, six (6) pages.

The Commissioner is hereby authorized to charge any deficiency or credit any excess to Deposit Account No. 14-0112.

Respectfully submitted,

**NATH & ASSOCIATES PLLC**

By: \_\_\_\_\_

*[Signature]*  
Gary M. Nath  
Registration No. 26,965  
Susanne M. Hopkins  
Registration No. 33,3247  
Ari G. Zytcer  
Registration No. 57,474  
Customer No. 20529

Date: April 11, 2006  
112 South West Street  
Alexandria, VA 22314  
TEL: (703) 548-6284  
FAX: (703) 683-8396



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of

Group Art Unit: 1631

YOKOYA *et al.*

Examiner: WHALEY, Pablo S.

Serial No.: 10/771,337

Filed: February 5, 2004

For: **GENE PANEL PARTICIPATIVE IN HEPATIC STELLATE CELL ACTIVATION**

**INFORMATION DISCLOSURE STATEMENT**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

An Information Disclosure Statement is submitted herewith pursuant to 37 C.F.R. § 1.97-1.98. Please note the following particulars:

**[NOTE: One only of items a, b, c, and d must be checked.]**

☒ a. The enclosed statement is being filed within three months of the filing date of a national application, or within three months of the date of entry into the national stage as set forth in 37 C.F.R. § 1.491 in an international application, or before the mailing date of a first Office Action on the merits, whichever event occurs last.

☐ b. The enclosed statement is being filed after a first action on the merits but before the mailing date of a final action under 37 C.F.R. § 1.113, or a notice of allowance under 37 C.F.R. § 1.311.

The enclosed statement is accompanied by [check one]:

- ☐ i. a certification in part (e) below as specified in 37 C.F.R. § 1.97(e), or  
☐ ii. a check in the amount required by 37 C.F.R. § 1.17(p).

☐ c. The enclosed statement is being filed after the mailing date of a final action under 37 C.F.R. § 1.113, or a notice of allowance under 37 C.F.R. § 1.311, but before payment of the issue fee.

- ☐ Certification report(e) below; and  
☐ a check in the amount as required by § 1.17(p).

☐ d. The enclosed statement is being filed pursuant to 37 C.F.R. § 1.97(i), for placement in the file.

☐ e. Certification [Check one] [Certification is required only if box (b)(i) or box (c) is checked.]

☐ I hereby certify that each item of information contained in the enclosed Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement,

or

☐ I hereby certify that no item of information in the enclosed Information Disclosure Statement herewith was cited in a communication from a foreign patent office in a counterpart foreign application, or, to my knowledge after making reasonable inquiry, was known to any individual designated in 37 C.F.R. § 1.56(c) more than three months prior to the filing of this Information Disclosure Statement.

or

☐ Appropriate certification is attached.

☒ f. If no check is enclosed and a fee is due in connection with this communication or if the check enclosed is insufficient, the Commissioner is authorized to charge any fee or additional fee due in connection with this communication to Deposit Account No. 14-0112.

☒ g. Copies of the documents are attached herewith with a completed Form PTO-1449.

And/or

☐ Copies of the documents are not attached as allowed under CFR 1.98(d)(1)(2). The earlier application is identified as:


or Copies of US Patents/Publications not attached as allowed in Official Gazette Aug. 5, 2003/ Vol. 1273, no. 1.

The Examiner is respectfully requested to cite the documents listed on the attached Form PTO-1449 in the next Office Action. In so doing, the Examiner is respectfully requested to initial in the space adjacent to the listing of each document on the Form PTO-1449, and return a copy of the initialed Form PTO-1449 with the next communication to Applicants, to confirm that these documents have been considered by the Examiner and made of record in this application.

If the Examiner has any questions or wishes to discuss this application, kindly telephone the undersigned at the below-listed number.

Respectfully submitted,  
**NATH & ASSOCIATES**

By:



Gary M. Nath  
Registration No. 26,965  
Susanne M. Hopkins  
Registration No. 33,247  
Ari G. Zytcer  
Registration No. 57,474  
Customer No. 20529

Date: April 11, 2006  
NATH & ASSOCIATES PLLC  
112 South West Street  
Alexandria, VA 22314  
Phone: 703-548-6284  
Fax: 703-683-8396



PTO/SB/08B (07-05)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Supplement for form 1449/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT***(Use as many sheets as necessary)***Complete if Known**

|                        |                  |
|------------------------|------------------|
| Application Number     | 10/771,337       |
| Filing Date            | FEBRUARY 5, 2004 |
| First Named Inventor   | YOKOYA et al.    |
| Art Unit               | 1631             |
| Examiner Name          | WHALEY, Pablo S. |
| Attorney Docket Number | 25908            |

|       |   |    |   |
|-------|---|----|---|
| Sheet | 1 | of | 1 |
|-------|---|----|---|

**NON PATENT LITERATURE DOCUMENTS**

| Examiner<br>Initials* | Cite<br>No. <sup>1</sup> | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of<br>the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue<br>number(s), publisher, city and/or country where published. | T <sup>2</sup> |
|-----------------------|--------------------------|---|----------------|
|                       | A1                       | STANTON, Lawrence W., "Methods to Profile Gene Expression," Trends<br>In Cardiovascular Med., Vol. II, No. 2 (2001) at 49-54.   |                |
|                       |                          |   |                |
|                       |                          |   |                |
|                       |                          |   |                |
|                       |                          |   |                |
|                       |                          |   |                |
|                       |                          |   |                |
|                       |                          |   |                |
|                       |                          |   |                |
|                       |                          |   |                |

|                       |  |                    |  |
|-----------------------|--|--------------------|--|
| Examiner<br>Signature |  | Date<br>Considered |  |
|-----------------------|--|--------------------|--|

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.